JPMorgan analyst Eric Joseph downgraded Karyopharm Therapeutics to Neutral and lowered his price target for the shares to $7 from $21. The analyst sees a “rocky regulatory road” forward for the company.
Friday, March 1, 2019
Stryker price target raised to $205 from $190 at Piper Jaffray
Piper Jaffray analyst Matt O’Brien raised his price target for Stryker to $205 saying he a found a “variety of data points” that suggest Mako placements and user penetration “are still in the early innings.” For hospitals with 50-plus beds, the penetration rate of one Mako system per hospital is still mid-teens, O’Brien tells investors in a research note. Further, the analyst found that nearly half of all orthopedic training programs have a Mako knee robot, “which provides a building pipeline of new users.” He reiterates an Overweight rating on Stryker shares.
https://thefly.com/landingPageNews.php?id=2872787
https://thefly.com/landingPageNews.php?id=2872787
Piper Jaffray loves the setup for CymaBay shares into NASH data
CymaBay’s Seladelpar has made “tremendous progress” in primary biliary cholangitis over the past year its competitive positioning continues to improve, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, the analyst believes the drug’s nonalcoholic steatohepatitis opportunity is not currently being factored into the existing valuation. The analyst expects to receive topline data from the ongoing Phase IIb trial of seladelpar in NASH next quarter. If successful, it could “multiply” the $750M PBC opportunity in his model, Van Buren says in a research note titled “We Love The Setup Of CBAY Here; Reiterate The Overweight.” He keeps a $30 price target on CymaBay shares.
https://thefly.com/landingPageNews.php?id=2872817
https://thefly.com/landingPageNews.php?id=2872817
Nektar price target lowered to $100 from $125 at Piper Jaffray.
Piper Jaffray analyst Tyler Van Buren lowered his price target for Nektar Therapeutics to $100 citing increased expenses flowing the company’s Q4 results. However, the analyst believes the company’s broader immunology pipeline is advancing nicely. He keeps an Overweight rating on the shares.
https://thefly.com/landingPageNews.php?id=2872819
https://thefly.com/landingPageNews.php?id=2872819
Subscribe to:
Posts (Atom)